Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis

BACKGROUND: Data on guideline-concordant initial systemic treatment among women with HER2-negative metastatic breast cancer (MBC) are limited. We determined the proportion of women with HER2-negative MBC who received guideline-concordant treatment and the extent to which independent variables explai...

Descripción completa

Detalles Bibliográficos
Autores principales: Vyas, Ami, Gabriel, Meghan, Kurian, Sobha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053132/
https://www.ncbi.nlm.nih.gov/pubmed/33880062
http://dx.doi.org/10.2147/BCTT.S295526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053132/
https://www.ncbi.nlm.nih.gov/pubmed/33880062
http://dx.doi.org/10.2147/BCTT.S295526

Ejemplares similares